Literature DB >> 15277272

Oxaliplatin in non-seminomatous germ-cell tumors.

K Fizazi, S Culine, I Chen.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15277272     DOI： 10.1093/annonc/mdh307

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  5 in total

Review 1.  Advances in the treatment of testicular cancer.

Authors:  Hans-Georg Kopp; Markus Kuczyk; Johannes Classen; Arnulf Stenzl; Lothar Kanz; Frank Mayer; Michael Bamberg; Jörg Thomas Hartmann
Journal:  Drugs       Date:  2006       Impact factor: 9.546

2.  Personalised chemotherapy based on tumour marker decline in poor prognosis germ-cell tumours (GETUG 13): a phase 3, multicentre, randomised trial.

Authors:  Karim Fizazi; Lance Pagliaro; Agnes Laplanche; Aude Fléchon; Josef Mardiak; Lionnel Geoffrois; Pierre Kerbrat; Christine Chevreau; Remy Delva; Frederic Rolland; Christine Theodore; Guilhem Roubaud; Gwenaëlle Gravis; Jean-Christophe Eymard; Jean-Pierre Malhaire; Claude Linassier; Muriel Habibian; Anne-Laure Martin; Florence Journeau; Maria Reckova; Christopher Logothetis; Stephane Culine
Journal:  Lancet Oncol       Date:  2014-11-13       Impact factor: 41.316

Review 3.  Current Management of Refractory Germ Cell Tumors and Future Directions.

Authors:  J Clayton Allen; Austin Kirschner; Kristen R Scarpato; Alicia K Morgans
Journal:  Curr Oncol Rep       Date:  2017-02       Impact factor: 5.075

Review 4.  Overcoming Chemotherapy Resistance in Germ Cell Tumors.

Authors:  Zuzana Országhová; Katarina Kalavska; Michal Mego; Michal Chovanec
Journal:  Biomedicines       Date:  2022-04-22

5.  Lenalidomide in patients with cisplatin-refractory and multiply relapsed germ cell tumors.

Authors:  Karin Oechsle; Carsten Bokemeyer; Friedemann Honecker
Journal:  J Cancer Res Clin Oncol       Date:  2009-09-16       Impact factor: 4.553
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.